Oncolytics Biotech
ONCY
34 hedge funds and large institutions have $1.43M invested in Oncolytics Biotech in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
61% more capital invested
Capital invested by funds: $887K → $1.43M (+$543K)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.1% less ownership
Funds ownership: 1.3% → 1.2% (-0.1%)
6% less funds holding
Funds holding: 36 → 34 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$134K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$56.6K |
| 3 |
Millennium Management
New York
|
+$39K |
| 4 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$38K |
| 5 |
VF
Virtu Financial
New York
|
+$37.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$20K |
| 2 |
DI
Disciplined Investments
Tulsa,
Oklahoma
|
-$6K |
| 3 |
TCOV
Trust Company of Vermont
Brattleboro,
Vermont
|
-$6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.65K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$3.04K |
ONCY Hedge Fund Activity: Q4 2022 in Review
34 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2022, worth a combined $1.43M — up 61% from $887K a quarter earlier.
Fund positioning in ONCY was balanced in Q4 2022: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $134K. The largest seller was LPL Financial, exiting entirely with an estimated $20K sold.
- 34 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2022, down from 36 in Q3 2022.
- Funds reported $1.43M of Oncolytics Biotech stock for Q4 2022, up 61% quarter-over-quarter.
- 6 funds opened new Oncolytics Biotech positions in Q4 2022 and 6 closed out, a net change of 0 holders.
- The largest Oncolytics Biotech buyer in Q4 2022 was Renaissance Technologies, an estimated $134K added.
- The largest Oncolytics Biotech seller in Q4 2022 was LPL Financial, an estimated $20K sold.
Based on aggregated 13F filings for Q4 2022.